Drugs / 131-I-MIP-1145
131-I-MIP-1145
also known as
BA-100 · Ioflubenzamida (131i) · Ioflubenzamide (131 i) · IOFLUBENZAMIDE I 131 · Mip-1145 i-131
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00747825 | Dec 2009 → Sep 2011 | metastatic melanoma | Molecular Insight Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 131-I-MIP-1145 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00747825 ↗ |
| Known as | BA-100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111095 ↗ |
| Known as | Ioflubenzamida (131i) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111095 ↗ |
| Known as | Ioflubenzamide (131 i) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111095 ↗ |
| Known as | IOFLUBENZAMIDE I 131 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111095 ↗ |
| Known as | Mip-1145 i-131 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111095 ↗ |
| Modality | Small molecule | — CHEMBL2111095 ↗ |
| Route | Intravenous | “administered via IV injection” NCT00747825 ↗ |